Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3] - The CEO, Michael A. Metzger, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025 [1] - A live webcast of the event will be available on the company's website, along with a replay for a limited time [2] Company Overview - Syndax's pipeline includes FDA-approved therapies such as Revuforj (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor [3] - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3]